Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Zealand Pharma A/S (22Z.F)

Compare
81.05
0.00
(0.00%)
As of March 3 at 7:06:21 PM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Adam Sinding Steensberg M.D. President & CEO 3.11M -- 1974
Ms. Henriette Wennicke EVP & CFO 1.37M -- 1983
Mr. Ivan Mourits Moller Executive VP & COO -- -- 1972
Mr. Ravinder Singh Chahil EVP & General Counsel -- -- 1968
Ms. Christina Sonnenborg Bredal Executive VP & Chief People Officer -- -- 1985
Dr. Jens Damsgaard Mikkelsen M.D. Head of Molecular Pharmacology -- -- --
Dr. David M. Kendall M.D. Executive VP, Chief Medical Officer & Head of R&D -- -- 1961
Mr. Eric Cox Executive VP & Chief Commercial Officer -- -- 1967
Miriam I. Katz Assistant Secretary -- -- --
Dr. Anna Krassowska Ph.D. Vice President of Investor Relations & Corporate Communications -- -- --

Zealand Pharma A/S

Sydmarken 11
Søborg, 2860
Denmark
45 88 77 36 00 https://www.zealandpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
335

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.

Corporate Governance

Zealand Pharma A/S’s ISS Governance QualityScore as of March 1, 2025 is 2. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 1; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 7, 2025 at 11:00 PM UTC

Zealand Pharma A/S Earnings Date

Recent Events

September 30, 2022 at 12:00 AM UTC

15F-12B: Notice of termination by a Foreign Private Issuer of a class of equity securities under Section 12(b)

September 20, 2022 at 12:00 AM UTC

25: Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange

September 7, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 31, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 10, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

June 2, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 26, 2022 at 12:00 AM UTC

S-8: Offering Registrations

May 24, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 20, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 16, 2022 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.